Current treatment options for invasive aspergillosis

Drugs of Today

Volumn 49, Issue 3, 2013, Pages 213-226

  Batista, Marjorie Vieira ^a   Costa, S F ^a   Shikanai Yasuda, M A ^a   Moss, R B ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amphotericin B; Antifungal drugs; Antifungal therapy; Azoles; Caspofungin; Echinocandins; Immunocompromised hosts; Invasive aspergillosis; Invasive fungal infection; Polyene antibiotics; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FEVER; FUNGICIDAL ACTIVITY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER DYSFUNCTION; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

AMPHOTERICIN B; ANTIFUNGAL DRUGS; ANTIFUNGAL THERAPY; AZOLES; CASPOFUNGIN; ECHINOCANDINS; IMMUNOCOMPROMISED HOSTS; INVASIVE ASPERGILLOSIS; INVASIVE FUNGAL INFECTION; POLYENE ANTIBIOTICS; VORICONAZOLE;

ANTIFUNGAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; INVASIVE PULMONARY ASPERGILLOSIS; LEUKOCYTE COUNT; OPPORTUNISTIC INFECTIONS; TIME FACTORS;

EID: 84875756916     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.3.1921234     Document Type: Review

References (84)

1. De Pauw, B., Walsh, T.J., Donnelly, J.P. et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46(12): 1813-21.
2. Steinbach, W.J., Marr, K.A., Anaissie, E.J. et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 2012, 65(5): 453-64.
3. Kontoyiannis, D.P., Marr, K.A., Park, B.J. et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010, 50(8): 1091-100.
4. Lin, S.J., Schranz, J., Teutsch, S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001, 32(3): 358-66.
5. Leeflang, M.M., Debets-Ossenkopp, Y.J., Visser, C.E. et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008(4): CD007394.
6. Bergeron, A., Porcher, R., Menotti, J. et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J Clin Microbiol 2012, 50(3): 823-30.
7. Theel, E.S., Jespersen, D.J., Iqbal, S. et al. Detection of (1, 3)- beta-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts. Mycopathologia 2013, 175(1-2): 33-41.
8. Metan, G., Koc, A.N., Kaynar, L.G., Atalay, A., Ozturk, A., Eser, B., Cetin, M. What is the role of the (1 - >3)-beta-D-glucan assay in the screening of patients undergoing autologous haematopoietic stem-cell transplantation? Mycoses 2013, 56(1): 34-8.
9. Bohme, A., Ruhnke, M., Buchheidt, D. et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009, 88(2): 97-110.
10. Walsh, T.J., Finberg, R.W., Arndt, C. et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999, 340(10): 764-71.
11. Walsh, T.J., Anaissie, E.J., Denning, D.W. et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46(3): 327-60.
12. Mehta, J., Kelsey, S., Chu, P. et al. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 1997, 20(1): 39-43.
13. Walsh, T.J., Hiemenz, J.W., Seibel, N.L. et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998, 26(6): 1383-96.
14. Oppenheim, B.A., Herbrecht, R., Kusne, S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995, 21(5): 1145-53.
15. Mills, W., Chopra, R., Linch, D.C., Goldstone, A.H. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994, 86(4): 754-60.
16. Ng, T.T., Denning, D.W. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995, 155(10): 1093-8.
17. Tollemar, J., Ringden, O., Ricci, P. et al. Early pharmacokinetic and clinical results from a non comparative multicentre trial of amphotericin B encapsulated in a small unilamellar liposome (AmBisome(R)). Drug Invest 1992, 4(3): 232-8.
18. Ringden, O., Meunier, F., Tollemar, J. et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991, 28(Suppl. B): 73-82.
19. Prentice, H.G., Hann, I.M., Herbrecht, R. et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997, 98(3): 711-8.
20. White, M.H., Bowden, R.A., Sandler, E.S. et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998, 27(2): 296-302.
21. Cornely, O.A., Maertens, J., Bresnik, M. et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44(10): 1289-97.
22. Caillot, D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol 2003, 109(3): 111-8.
23. Denning, D.W., Lee, J.Y., Hostetler, J.S. et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994, 97(2): 135-44.
24. Prentice, A.G., Glasmacher, A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005, 56(Suppl. 1): i17-i22.
25. Persat, F., Marzullo, C., Guyotat, D., Rochet, M.J., Piens, M.A. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992, 28A(4-5): 838-41.
26. Feola, D., Rapp, R.P. Effect of food intake on the bioavailability of itraconazole. Clin Infect Dis 1997, 25(2): 344-5.
27. Theuretzbacher, U., Ihle, F., Derendorf, H. Pharmaco - kinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006, 45(7): 649-63.
28. Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M.J., Kleinermans, D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002, 46(8): 2546-53.
29. Herbrecht, R., Denning, D.W., Patterson, T.F. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347(6): 408-15.
30. Blot, F., Ede, C., Nitenberg, G.M. Voriconazole versus amphotericin B for invasive aspergillosis. N Engl J Med 2002, 347(25): 2080-1.
31. Karthaus, M. Voriconazole versus amphotericin B for invasive aspergillosis. N Engl J Med 2002, 347(25): 2080-1.
32. Walsh, T.J., Pappas, P., Winston, D.J. et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346(4): 225-34.
33. Perfect, J.R., Marr, K.A., Walsh, T.J. et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36(9): 1122-31.
34. Johnson, J.R. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med 2002, 346(22): 1745-7.
35. Ide, L., Buysschaert, I., Demuynck, H., De Man, R., Verlinde, A., De Laere, E., Surmont, I. Zygomycosis in neutropenic patients with past Aspergillus infection: a role for posaconazole? Clin Microbiol Infect 2004, 10(9): 862-3.
36. Mellinghoff, I.K., Winston, D.J., Mukwaya, G., Schiller, G.J. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002, 34(12): 1648-50.
37. Pitisuttithum, P., Negroni, R., Graybill, J.R. et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005, 56(4): 745-55.
38. Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., Marchetti, O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008, 46(2): 201-11.
39. Maertens, J., Raad, I., Petrikkos, G. et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39(11): 1563-71.
40. Douglas, C.M. Fungal beta(1,3)-D-glucan synthesis. Med Mycol 2001, 39(Suppl. 1): 55-66.
41. Walsh, T.J., Teppler, H., Donowitz, G.R. et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004, 351(14): 1391-402.
42. Kontoyiannis, D.P., Lewis, R.E. Caspofungin versus liposomal amphotericin B for empirical therapy. N Engl J Med 2005, 352(4): 410-4.
43. Cappelletty, D., Eiselstein-McKitrick, K. The echinocandins. Pharmacotherapy 2007, 27(3): 369-88.
44. Stone, J.A., Holland, S.D., Wickersham, P.J. et al. Singleand multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002, 46(3): 739-45.
45. Denning, D.W., Marr, K.A., Lau, W.M. et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006, 53(5): 337-49.
46. Verweij, P.E., van de Sande-Bruisma, N., Kema, G.H., Melchers, W.J. [Azole resistance in Aspergillus fumigatus in the Netherlands - increase due to environmental fungicides?]. Ned Tijdschr Geneeskd 2012, 156(25): A4458.
47. Diaz-Guerra, T.M., Mellado, E., Cuenca-Estrella, M., Rodriguez-Tudela, J.L. A point mutation in the 14alphasterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2003, 47(3): 1120-4.
48. Lockhart, S.R., Frade, J.P., Etienne, K.A., Pfaller, M.A., Diekema, D.J., Balajee, S.A. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2012, 55(9): 4465-8.
49. van der Linden, J.W., Snelders, E., Kampinga, G.A. et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 2011, 17(10): 1846-54.
50. Tashiro, M., Izumikawa, K., Minematsu, A. et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother 2012, 56(1): 584-7.
51. Howard, S.J., Cerar, D., Anderson, M.J. et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009, 15(7): 1068-76.
52. Masia Canuto, M., Gutierrez Rodero, F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002, 2(9): 550-63.
53. Mortensen, K.L., Johansen, H.K., Fuursted, K. et al. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur J Clin Microbiol Infect Dis 2011, 30(11): 1355-63.
54. Maertens, J., Marchetti, O., Herbrecht, R. et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3 - 2009 update. Bone Marrow Transplant 2011, 46(5): 709-18.
55. Steinbach, W.J., Stevens, D.A., Denning, D.W. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003, 37(Suppl. 3): S188-224.
56. Popp, A.I., White, M.H., Quadri, T., Walshe, L., Armstrong, D. Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study. Int J Infect Dis 1999, 3(3): 157-60.
57. Marr, K.A., Boeckh, M., Carter, R.A., Kim, H.W., Corey, L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39(6): 797-802.
58. Kontoyiannis, D.P., Boktour, M., Hanna, H., Torres, H.A., Hachem, R., Raad, II Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 2005, 103(11): 2334-7.
59. Singh, N., Limaye, A.P., Forrest, G. et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006, 81(3): 320-6.
60. Upton, A., Kirby, K.A., Carpenter, P., Boeckh, M., Marr, K.A. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007, 44(4): 531-40.
61. Raad, II, Hanna, H.A., Boktour, M. et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008, 22(3): 496-503.
62. Caillot, D., Thiebaut, A., Herbrecht, R. et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007, 110(12): 2740-6.
63. Mihu, C.N., Kassis, C., Ramos, E.R., Jiang, Y., Hachem, R.Y., Raad, II Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer 2010, 116(22): 5290-6.
64. Lellek, H., Waldenmaier, D., Dahlke, J., Ayuk, F.A., Wolschke, C., Kroger, N., Zander, A.R. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients. Mycoses 2011, 54(Suppl. 1): 39-44.
65. Goodman, J.L., Winston, D.J., Greenfield, R.A. et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326(13): 845-51.
66. Slavin, M.A., Osborne, B., Adams, R. et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, doubleblind study. J Infect Dis 1995, 171(6): 1545-52.
67. Marr, K.A., Seidel, K., Slavin, M.A. et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000, 96(6): 2055-61.
68. Jantunen, E., Ruutu, P., Niskanen, L., Volin, L., Parkkali, T., Koukila-Kahkola, P., Ruutu, T. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997, 19(8): 801-8.
69. Marr, K.A., Carter, R.A., Crippa, F., Wald, A., Corey, L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34(7): 909-17.
70. Marr, K.A., Crippa, F., Leisenring, W. et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004, 103(4): 1527-33.
71. Wingard, J.R., Carter, S.L., Walsh, T.J. et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010, 116(24): 5111-8.
72. Skiada, A., Pagano, L., Groll, A. et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011, 17(12): 1859-67.
73. van Burik, J.A., Ratanatharathorn, V., Stepan, D.E. et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004, 39(10): 1407-16.
74. Ullmann, A.J., Lipton, J.H., Vesole, D.H. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356(4): 335-47.
75. Cornely, O.A., Maertens, J., Winston, D.J. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356(4): 348-59.
76. Auberger, J., Lass-Florl, C., Aigner, M., Clausen, J., Gastl, G., Nachbaur, D. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother 2012, 67(9): 2268-73.
77. Powers, J.H., Dixon, C.A., Goldberger, M.J. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl J Med 2002, 346(4): 289-90.
78. Marr, K.A. Empirical antifungal therapy - new options, new tradeoffs. N Engl J Med 2002, 346(4): 278-80.
79. Bowden, R., Chandrasekar, P., White, M.H. et al. A doubleblind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002, 35(4): 359-66.
80. Ellis, M., Spence, D., de Pauw, B. et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998, 27(6): 1406-12.
81. White, M.H., Anaissie, E.J., Kusne, S. et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997, 24(4): 635-42.
82. Perfect, J.R., Klotman, M.E., Gilbert, C.C., Crawford, D.D., Rosner, G.L., Wright, K.A., Peters, W.P. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992, 165(5): 891-7.
83. Uppin, M.S., Anuradha, S.V., Uppin, S.G., Paul, T.R., Prayaga, A.K., Sundaram, C. Fungal infections as a contributing cause of death: an autopsy study. Indian J Pathol Microbiol 2011, 54(2): 344-9.
84. Graf, K., Khani, S.M., Ott, E. et al. Five-years surveillance of invasive aspergillosis in a university hospital. BMC Infect Dis 2011, 11: 163.